Skip to Main Content

Paper Details

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Cancer Cell
206
2019
B cell lymphoma, B cell lymphoma 2, BCL-2, BCL-2 family members, BCL-2-driven OCI-Ly1 lymphoma cell line, Lymphoid, Lymphoid Malignancies, chronic lymphocytic leukemia, drug-resistant, engineered cell lines, lymphoid malignancies, patient, venetoclax
Author NameAffiliation
Daniel RosebrockBroad Institute of MIT and Harvard
Dimitri LivitzBroad Institute of MIT and Harvard
Donna NeubergHarvard Medical School, Dana-Farber Cancer Institute
J. Wade HarperHarvard Medical School
Steven A CarrBroad Institute of MIT and Harvard
Steven A CarrBroad Institute of MIT and Harvard
Federica PiccioniBroad Institute of MIT and Harvard
Ignaty LeshchinerBroad Institute of MIT and Harvard
John G DoenchBroad Institute of MIT and Harvard
Vamsi K MoothaBroad Institute of MIT and Harvard, USA Harvard Medical School, USA Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital
Vamsi K MoothaBroad Institute of MIT and Harvard, USA Harvard Medical School, USA Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital
Gad GetzBroad Institute of MIT and Harvard, USA Harvard Medical School, USA Massachusetts General Hospital Cancer Center
Gad GetzBroad Institute of MIT and Harvard, USA Harvard Medical School, USA Massachusetts General Hospital Cancer Center
Catherine J WuDana-Farber Cancer Institute, USA Broad Institute of MIT and Harvard, USA Harvard Medical School, Brigham and Women's Hospital
  • 1 - 14

Datasets